The effect of trimetazidine on left ventricular systolic function and physical tolerance in patients with ischaemic cardiomyopathy

Acta Cardiologica

Volumn 62, Issue 5, 2007, Pages 493-499

  Sisakian, Hamayak ^a   Torgomyan, Adrina ^a   Barkhudaryan, Anush ^a  

^a YEREVAN STATE MEDICAL UNIVERSITY   (Armenia)

Author keywords

Chronic heart failure; Ejection fraction; Ischaemic cardiomyopathy; Physical tolerance; Trimetazidine

Indexed keywords

TRIMETAZIDINE;

ADULT; AGED; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; FEMALE; HEART LEFT VENTRICLE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE;

AGED; CARDIOMYOPATHY, DILATED; CARDIOTONIC AGENTS; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEALTH STATUS INDICATORS; HEART FAILURE; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; MYOCARDIAL ISCHEMIA; PROSPECTIVE STUDIES; STROKE VOLUME; SYSTOLE; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 35348894339     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.62.5.2023413     Document Type: Article

References (32)

1. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive Summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001; 104: 2996-3007.
2. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107-15.
3. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347:1397-402.
4. Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, Kukin ML. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation 1987; 75(5 Pt 2): IV80-92.
5. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, Shelton B. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 1995; 91: 2573-81.
6. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984; 101: 370-7.
7. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580-8.
8. Lopaschuk GD. Optimizing cardiac energy metabolism: a new approach to treating ischemic heart disease. Eur Heart J 1999; 1 Suppl O: O32-9.
9. Brottier L, Barat JL, Combe C, Boussens B, Bonnet J, Bricaud H. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J 1990; 11: 207-12.
10. Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, Volterrani M, Rosano GM. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004; 25: 1814-21.
11. D'hahan N, Taouil K, Dassouli A, Morel JE. Long-term therapy with trimetazidine in cardiomyopathic Syrian hamster BIO 14:6. Eur J Pharmacol 1997; 328: 163-74.
12. Lu C, Dabrowski P, Fragasso G, Chierchia SL. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1998; 82: 898-901.
13. Rosano GM, Vitale C, Sposato B, Mercuro G, Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 2003; 2: 16.
14. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of two-dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-67.
15. Guyatt GH, Sullivan MJ, Thompson PL, Fallen EL, Pugsley SO, Taylor DW, Berman LB. The six-minute walk test: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985; 132: 919-23.
16. Knox AJ, Morrison JF, Muers MF. Reproducibility of walking test results in chronic obstructive airways disease. Thorax 1988; 43: 388-92.
17. Shah MR, Hasselblad V, Gheorghiade M, Adams KF Jr, Swedberg K, Califf RM, O'Connor CM. Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or non-ischemic cardiomyopathy. Am J Cardiol 2001; 88: 987-93.
18. Rostagno C, Olivo G, Comeglio M, Boddi V, Banchelli M, Galanti G, Gensini GF. Prognostic value of 6-min walk corridor test in patients mild to moderate heart failure: comparison with other methods of functional evaluation. Eur J Heart Fail 2003; 5: 247-52.
19. Cazeau S, Leclerc C, Lavergne T, Walker S, Varna C, Linde C, Garrigue S, Kappenberger L, Haywood GA, Santini M, Bailleul C, Daubert JC. Multisite Stimulationin in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. New Engl J Med 2001; 344: 873-80.
20. Sisakian HS. New therapeutic approach in chronic heart failure: metabolic intervention with trimetazidine. Heart and Metabolism 2005; 26: 23-6.
21. Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischemic cardiomyopathy. Eur Heart J 2001; 22: 2164-70.
22. Di Napoli P, Taccardi AA, Barsotti A. Long-term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischemic dilated cardiomyopathy. Heart 2005; 91: 161-5.
23. Fragasso G, Piatti Md PM, Monti L, Palloshi A, Setola E, Puccetti P, Calori G, Lopaschuk GD, Margonato A. Short-and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 2003; 146: E18.
24. Lopaschuk GP. Modulation of energy metabolism as an approach to treating heart failure. Cardiovasc J S Afr 2004; 15 suppl 45: 52.
25. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions. Potential for pharmacological interventions. Cardiovasc Res 1997; 33: 243-57.
26. 2+ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther 1988; 1: 677-86.
27. Randle PJ, Newsholme EA, Garland PB. Regulation of glucose uptake by muscle. Biochem J 1964; 93: 652-65.
28. King LM, Opie LH. Glucose and glycogen utilization in myocardial ischemia - changes in metabolism and consequences for the myocyte. Mol Cell Biochem 1998; 180: 3-26.
29. Williams FM, Tanda K, Kus M, Williams TJ. Trimetazidine inhibits neutrophil accumulation after myocardial ischemia and reperfusion in rabbits. J Cardiovasc Pharmacol 1993; 22: 828-33.
30. Knight C, Fox K. From antianginal drugs to myocardial cytoprotective agents. Am J Cardiol 1995; 76: 4B-7B.
31. Boffa GM, Zaninotto M, Nalli C, Forni M, Tiso E, Razzolini R, Plebani M. Plasma levels of tumor necrosis factor-alpha correlate with the six-minute walk test results in patients with mild to moderate heart failure. Ital Heart J 2004; 5: 48-52.
32. LeMaitre JP, Harris S, Fox KA, Denvir M. Change in circulating cytokines after 2 forms of exercise training in chronic stable heart failure. Am Heart J 2004; 147: 100-5.